Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro
- PMID: 8993319
- DOI: 10.1021/bi962148u
Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro
Abstract
Liposomes (70-100 nm) of 1-palmitoyl-2-oleoylphosphatidylcholine, cholesterol, and poly(ethylene glycol) (PEG)-modified phosphatidylethanolamine (PEG-DSPE) were conjugated to Fab' fragments of a humanized recombinant MAb against the extracellular domain of HER2/neu to create sterically stabilized immunoliposomes (anti-HER2 SL) as a drug carrier targeting HER2-overexpressing cancers. Conjugation employed maleimide-terminated membrane-anchored spacers of two kinds: a short spacer, providing attachment of Fab' close to the liposome bilayer, or a long spacer, with Fab' attachment at the distal terminus of the PEG chain. Confocal microscopy and spectrofluorometry of HER2-overexpressing breast cancer cells incubated with fluorescently labeled anti-HER2 SL prepared with either spacer showed binding of liposomes (8000-23000 vesicles/cell) followed by endocytosis (rate constant ke = 0.012-0.033 min-1) via the coated-pit pathway, evidenced by intracellular acidification and colocalization with transferrin. Uptake of anti-HER2 immunoliposomes by breast cancer cells with low HER2 expression, or after preincubation of cells with free anti-HER2 Fab', was less than 0.2% and 4.3%, respectively, of the uptake by HER2-overexpressing cells. Increasing PEG-DSPE content (up to 5.7 mol %) in anti-HER2-SL prepared with the short spacer decreased liposome-cell binding affinity 60-100-fold, while ke decreased only 2-fold; however, when Fab' fragments were conjugated via a PEG spacer, both binding affinity and ke were unaffected by PEG-DSPE content. Cell binding and internalization of anti-HER2 immunoliposomes increased at higher surface density of conjugated Fab' fragments, reaching plateaus at approximately 40 Fab'/liposome for binding and approximately 10-15 Fab'/liposome for internalization. Uptake of anti-HER2 immunoliposomes correlated with the cell surface density of HER2 and significantly (p < 0.005) correlated with the antiproliferative effect of the targeting antibody but not with the total level of cellular HER2 expression. The results obtained were used to optimize in vivo preclinical studies of anti-HER2 SL loaded with antineoplastic drugs.
Similar articles
-
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.Cancer Res. 2006 Jul 1;66(13):6732-40. doi: 10.1158/0008-5472.CAN-05-4199. Cancer Res. 2006. PMID: 16818648
-
Lymphoid tissue targeting of anti-HIV drugs using liposomes.Methods Enzymol. 2005;391:330-51. doi: 10.1016/S0076-6879(05)91019-7. Methods Enzymol. 2005. PMID: 15721390
-
Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.Cancer Res. 2000 Dec 15;60(24):6942-9. Cancer Res. 2000. PMID: 11156394
-
[PEG-liposome in DDS and clinical studies].Nihon Rinsho. 1998 Mar;56(3):632-7. Nihon Rinsho. 1998. PMID: 9549348 Review. Japanese.
-
PEG-immunoliposome.Biosci Rep. 2002 Apr;22(2):251-66. doi: 10.1023/a:1020138622686. Biosci Rep. 2002. PMID: 12428903 Review.
Cited by
-
Approaches to Characterize and Quantify Extracellular Vesicle Surface Conjugation Efficiency.Life (Basel). 2024 Apr 15;14(4):511. doi: 10.3390/life14040511. Life (Basel). 2024. PMID: 38672781 Free PMC article. Review.
-
Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation.Invest New Drugs. 2023 Oct;41(5):664-676. doi: 10.1007/s10637-023-01372-5. Epub 2023 Aug 5. Invest New Drugs. 2023. PMID: 37542666
-
Effects of PEG-Linker Chain Length of Folate-Linked Liposomal Formulations on Targeting Ability and Antitumor Activity of Encapsulated Drug.Int J Nanomedicine. 2023 Mar 30;18:1615-1630. doi: 10.2147/IJN.S402418. eCollection 2023. Int J Nanomedicine. 2023. PMID: 37020691 Free PMC article.
-
Recent Preclinical and Clinical Progress in Liposomal Doxorubicin.Pharmaceutics. 2023 Mar 9;15(3):893. doi: 10.3390/pharmaceutics15030893. Pharmaceutics. 2023. PMID: 36986754 Free PMC article. Review.
-
Lipid nanoparticle-mediated mRNA delivery in lung fibrosis.Eur J Pharm Sci. 2023 Apr 1;183:106370. doi: 10.1016/j.ejps.2023.106370. Epub 2023 Jan 13. Eur J Pharm Sci. 2023. PMID: 36642345 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous